text.skipToContent text.skipToNavigation
Need help? Please contact us

Human Hepatocytes, Cryopreserved, Plateable and Interaction Qualified

Catalog #: HUCPI

Cryopreserved Human Hepatocytes, Plateable and Interaction Qualified are characterized for 3 major mechanisms of Drug-Drug interactions: transporter activity, enzyme activity, and induction potential, providing you with one product to meet more of your hepatocyte DDI study needs  Each ampule contains >5 million cells. 

 

 1’894.00 CHF
Compare
AMP

Product Overview

Clinically relevant drug-drug interactions (DDI) are a serious concern for any new drug development project.

To better support capturing the multiple mechanisms of DDI potential using cryopreserved primary human hepatocytes, we now offer Interaction Qualified Cryopreserved Human Hepatocytes (Catalog HUCPI) which are characterized for 3 major mechanisms of DDI:

  • Transporter activity
  • Enzyme activity
  • Enzyme gene induction potential. 

Interaction Qualified Cryopreserved Human Hepatocytes have the following features and benefits:

Benefits

  • Use the same donor for basal clearance, transport, and induction studies
  • Actual rates of transport reported rather than relative rates for less ambiguity
  • Large lots mean fewer rounds of testing so you can focus on results
  • Prequalified in Lonza media for better reproducibility

Features*:

  • Confluent monolayer with cobblestone morphology, distinct nuclei, and tight junctions for 5 days or more
  • Inducibility of enzyme activity for CYP3A4, CYP2B6, and CYP1A2
  • Inducibility of mRNA for CYP3A4, CYP2B6, CYP1A2, and CYP2C8 genes
  • Actual rate of uptake or efflux for OATP1B1/3, OCT1/2, NTCP, and BSEP** transporters
  • Differences in passive vs. active uptake for OATP1B1/3, OCT1/2, and NTCP transporters.
  • Basal metabolism for 8 CYPs, SULT, UGT, and aldehyde oxidase
  • Plated low-turnover clearance for CYP2C9, CYP2D6, and CYP3A4
  • Complementary thawing, plating, and maintenance medium available
  • > 5 million viable cells/vial
  • Characterized for long-term culture potential (> 7 days)
  • Characterized for spheroid formation potential

 

Our qualification methods for cryopreserved human hepatocytes are modelled after recommendations from the FDA publication In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry (2017, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm) .

*Currently, older batches may not have a complete data set of characteristics listed

***BSEP efflux activity is measured using method described in Jie Zhang, et al., Chemico-Biological Interactions, Volume 255, 2016, Pages 45-54,

Benefits

  • Use the same donor for basal clearance, transport, and induction studies
  • Actual rates of transport reported rather than relative rates for less ambiguity
  • Large lots mean fewer rounds of testing so you can focus on results
  • Prequalified in Lonza media for better reproducibility
  • Pre-tested for long-term culture, spheroid formation, and 96-well compatibility

Applications

  • Drug-Drug interaction studies
  • Low clearance metabolism studies
  • Drug uptake and efflux
  • Disease modeling
  • Xenotransplantation
  • Short term cellular toxicity studies
  • 3D cell culture

Content & Storage

Content

Cryopreserved ampule of HUCPI containing >5 million viable cells

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Hepatic Cell Inventories

Human Hepatocytes, Animal Hepatocytes, Hepatic Non-Parenchymal Cells

View donor information and select characteristics of currently available hepatic cell lots.

Interested in our Webinars?

Need a break from your daily routine? Grab a coffee and check out our free webinars. 

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.